Quanterix and Innovita Extend the Biomarker Platform Play Into China’s Regulated Neurology Market

Quanterix and Innovita are turning biomarker platforms into regulated neurology testing infrastructure in China, with approvals that expand both clinical reach and recurring assay revenue.

Updated

What is this trend?

Quanterix and Innovita’s NMPA approvals for HD-X, SR-X, and four neurology biomarker kits signal that biomarker platforms are moving from research tools into regulated neurodegeneration testing in China.

  • China approval covers instruments plus p-Tau 217, GFAP, p-Tau 181, and NfL kits
  • Platform value is shifting from single assays to recurring reagent pull-through
  • Local regulatory execution is becoming a key moat in neurology diagnostics
  • The same Simoa backbone is expanding across regulated and RUO biomarker use cases

What’s the latest?

Archived neonatal dried blood spots from 652 of 2,652 reviewed under-five deaths were analyzed with tandem mass spectrometry across a 43-metabolite panel, then confirmed by whole-exome sequencing to i

Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidates

How it developed

  1. Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision support
    • Blood-Based Cancer Screening Moves From Assay Novelty to Workflow Integration

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Related trends

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.